Inhibitors of intracellular phospholipase A2 activity: Their neurochemical effects and therapeutical importance for neurological disorders

Brain Research Bulletin

Volumn 49, Issue 3, 1999, Pages 139-153

  Farooqui, Akhlaq A ^a   Litsky, Monica L ^a   Farooqui, Tahira ^a   Horrocks, Lloyd A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Arachidonic acid; Eicosanoids; Ischemia; Signal transduction; Spinal cord injury

Indexed keywords

4 BROMOPHENACYL BROMIDE; ALPHA TOCOPHEROL; ARISTOLOCHIC ACID; CALCIUM BINDING PROTEIN; CITICOLINE; GANGLIOSIDE; HEPARIN; ICOSANOID; INDOMETACIN; LIPOCORTIN; MANOALIDE; MEPACRINE; N ACETYLNEURAMINIC ACID; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; SURFACTIN; THROMBOCYTE ACTIVATING FACTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG PENETRATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; ENZYMOLOGY; IN VIVO STUDY; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

ANIMALS; BRAIN CHEMISTRY; CARBOHYDRATE SEQUENCE; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; NERVOUS SYSTEM DISEASES; PHOSPHOLIPASES A;

EID: 0033062508     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(99)00027-1     Document Type: Review

References (143)

1. 2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. 270:1995;445-450.
2. 2. Biochim. Biophys. Acta Lipids Lipid Metab. 1259:1995;125-136.
3. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Biochem. Sci. 18:1997;12-18.
4. Ala T., Romero S., Knight F., Feldt K., Frey W.H. II. GM-1 treatment of Alzheimer's Disease. A pilot study of safety and efficacy. Arch. Neurol. 47:1990;1126-1130.
5. 2. Eur. J. Pharmacol. 326:1997;237-250.
6. 2 and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit. Biochem. Pharmacol. 36:1987;3697-3700.
7. 1 macrophages and Chinese hamster ovary cells. J. Biol. Chem. 272:1997;8576-8580.
8. 2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. J. Biol. Chem. 272:1997;29317-29321.
9. 2 in arachidonic acid metabolism in P388D1 macrophages. Adv. Exp. Med. Biol. 407:1996;99-103.
10. 2. J. Biol. Chem. 272:1997;16069-16072.
11. 2 inhibit release of free arachidonate in thrombin-stimulated human platelets. J. Biol. Chem. 269:1994;15625-15630.
12. Berlett B.S., Stadtman E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272:1997;20313-20316.
13. Black M.D., Carey F., Crossman A.R., Relton J.K., Rothwell N.J. Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res. 585:1992;135-140.
14. Bressler J.P., Belloni-Olivi L., Forman S. Effect of ganglioside GM1 on arachidonic acid release in bovine aortic endothelial cells. Life Sci. 54:1994;49-60.
15. 2 activity in vitamin E and selenium-deficient rat lung, liver, and spleen cytosol is time-dependent and reversible. J. Nutr. Biochem. 7:1996;366-374.
16. 2 after UVB injury. Biochim. Biophys. Acta Lipids Lipid Metab. 1299:1996;23-33.
17. Choe M., Jackson C., Yu B.P. Lipid peroxidation contributes to age-related membrane rigidity. Free Radic. Biol. Med. 18:1995;977-984.
18. 2. J. Lipid Mediat. Cell Signal. 12:1995;83-117.
19. 2 after transient global forebrain ischemia in the rat. Stroke. 27:1996;527-535.
20. Dash P.K., Moore A.N. Enhanced processing of APP induced by IL-1β can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem. Biophys. Res. Commun. 208:1995;542-548.
21. Dean R.T., Fu S., Stocker R., Davies M.J. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J. 324:1997;1-18.
22. 2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1997;1-2.
23. Deutsch J., Rapoport S.I., Purdon A.D. Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation. Neurochem. Res. 22:1997;759-765.
24. Dixon C.E., Ma X., Marion D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma. 14:1997;161-169.
25. Domin J., Higgins T., Rozengurt E. Preferential inhibition of platelet-derived growth factor-stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. J. Biol. Chem. 269:1994;8260-8267.
26. 2. Biochim. Biophys. Acta. 876:1986;639-645.
27. Dubin N.H., Blake D.A., DiBlasi M.C., Parmley T.H., King T.M. Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys. Fertil. Steril. 38:1982;735-740.
28. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48:1996;1-19.
29. 2 in brain during ischemia. J. Neurochem. 39:1982;1111-1116.
30. 2 with anti-inflammatory activity . J. Pharmacol. Exp. Ther. 282:1997;123-131.
31. 2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res. 752:1997;203-208.
32. Farooqui A.A., Haun S.E., Horrocks L.A. Ischemia and hypoxia. Siegel G.J., Agranoff B.W., Albers R.W., Molinoff P.B. Basic neurochemistry. 1994;867-883 Raven Press, New York.
33. Farooqui A.A., Hirashima Y., Horrocks L.A. Brain phospholipases and their role in signal transduction. Bazan N.G., Toffano G., Murphy M. Neurobiology of essential fatty acids. 1992;11-25 Plenum Press, New York.
34. Farooqui A.A., Horrocks L.A. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res. Rev. 16:1991;171-191.
35. Farooqui A.A., Horrocks L.A. Excitotoxicity and neurological disorders Involvement of membrane phospholipids . Int. Rev. Neurobiol. 36:1994;267-323.
36. Farooqui A.A., Liss L., Horrocks L.A. Elevated activities of lipases and lysophospholipases in Alzheimer's disease. Dementia. 1:1990;208-214.
37. Farooqui A.A., Taylor W.A., Horrocks L.A. Phospholipases, lysophospholipases and lipases and their involvement in various diseases. Neurochem. Pathol. 7:1987;99-128.
38. Farooqui A.A., Yang H.-C., Horrocks L.A. Purification of lipases, phospholipases and kinases by heparin-Sepharose chromatography. J. Chromatogr. 673:1994;149-158.
39. 2, and signal transduction. Brain Res. Rev. 21:1995;152-161.
40. 2 in neurodegeneration. Neurochem. Int. 30:1997;517-522.
41. 2 and its role in brain tissue. J. Neurochem. 69:1997;889-901.
42. Fernando S.R., Pertwee R.G. Evidence that methyl arachidonyl fluorophosphate is an irreversible cannabinoid receptor antagonist. Br. J. Pharmacol. 121:1997;1716-1720.
43. 2 inhibitor. Dev. Brain Res. 78:1994;81-86.
44. 1 treatment for Alzheimer's disease. Am. J. Psychiatry. 151:1994;126-129.
45. Friguet B., Stadman E., Szweda L. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. J. Biol. Chem. 269:1994;21639-21643.
46. 2 by a manoalide analogue. Biochem. J. 308:1995;297-304.
47. 2 inhibition. Life Sci. 51:1992;77-81.
48. 1 ganglioside. N. Engl. J. Med. 324:1991;1829-1887.
49. Gerke V., Moss S.E. Annexins and membrane dynamics. Biochim. Biophys. Acta Mol. Cell Res. 1357:1997;129-154.
50. Ginsburg I., Mitra R.S., Gibbs D.F., Varani J., Kohen R. Killing of endothelial cells and release of arachidonic acid. Inflammation. 17:1993;295-319.
51. 2 enzymes Regulation and inhibition . Trends Pharmacol. Sci. 14:1993;92-98.
52. 2 activity from the 106000 × g pellet (microsomal fraction) of bovine brain acting on phosphatidylinositol. Can. J. Biochem. 60:1982;108-117.
53. 2 by phosphorylation in rat mesangial cells. J. Clin. Invest. 93:1994;1224-1233.
54. Hall E.D., Yonkers P.A., Andrus P.K., Cox J.W., Anderson D.K. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J. Neurotrauma. 9:(suppl. 2):1992;S425-S442.
55. Hardy J. The Alzheimer family of diseases Many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA. 94:1997;2095-2097.
56. 2. Implications for the coordinated regulation of phospholipolysis and glycolysis. J. Biol. Chem. 268:1993;9892-9900.
57. 2. J. Biol. Chem. 265:1990;10622-10630.
58. 1 ganglioside treatment of spontaneously hypertensive stroke prone rats. Exp. Neurol. 126:1994;95-100.
59. 2 from bovine brain cytosol. J. Neurochem. 59:1992;708-714.
60. 2 inhibitor in a passive avoidance task in the chick. Neurobiol. Learn. Mem. 63:1995;206-208.
61. 2 produce amnesia for a passive avoidance task in the chick. Behav. Neural. Biol. 61:1994;225-232.
62. 2. Agents Actions. 39:1993;C39-C42.
63. 2. Biochemistry. 35:1996;3712-3721.
64. +-ATPase activity by oxygen free radicals. Neuroreport. 7:1995;333-337.
65. Käfer A., Krug H.F. Effects of organometals on cellular signaling. I. Influence of metabolic inhibitors on metal-induced arachidonic acid liberation. Environ. Health Perspect. 102:(suppl. 3):1994;325-330.
66. Keyser D.O., Alger B.E. Arachidonic acid modulates hippocampal calcium current via protein kinase C and oxygen radicals. Neuron. 5:1990;545-553.
67. 2. Biochem. Pharmacol. 55:1998;975-985.
68. 2 and properties of the expressed protein. J. Biochem. 272:1997;2542-2550.
69. Kooy N., Royall J., Ischoropoulos H., Beckman J. Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free Radic. Biol. Med. 16:1994;149-156.
70. 2) and lipid mediator release in the brain. J. Lipid Mediat. Cell Signal. 14:1996;3-7.
71. 2. J. Biol. Chem. 268:1993;20713-20716.
72. 2. Arch. Pharm. Pharm. Med. Chem. 329:1996;483-488.
73. 2. Arch. Pharm. Pharm. Med. Chem. 329:1996;386-392.
74. 2 Variation of the alkanoic acid substituent, the acyl chain and the position of the pyrrole nitrogen . Eur. J. Med. Chem. 32:1997;805-814.
75. 2. J. Med. Chem. 40:1997;2694-2705.
76. 2. J. Biol. Chem. 272:1997;16709-16712.
77. Levi A., Biocca S., Cataneo A., Calissano P. The mode of action of nerve growth factor in PC12 cells. Mol. Neurobiol. 2:1989;201-226.
78. 2 in activated human monocytes Regulation of superoxide anion production and low density lipoprotein oxidation . J. Biol. Chem. 272:1997;2404-2411.
79. 2 by quercetin. Inflammation. 17:1993;573-582.
80. 2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta Lipids Lipid Metab. 1302:1996;55-60.
81. 2. J. Biol. Chem. 271:1996;6010-6016.
82. 3, inhibits glucose-induced insulin secretion from isolated rat islets. Biochem. Biophys. Res. Commun. 218:1996;423-427.
83. 2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J. Biochem. 272:1997;11118-11127.
84. 2 does not alter leukotriene formation. J. Biol. Chem. 272:1997;759-765.
85. McCormick D.L., Spicer A.M. Nordihydroguaiaretic acid suppression of rat mammary carcinogogenesis induced by N-methyl-N-nitrosourea. Cancer Lett. 37:1987;139-146.
86. Michel M.C. Making sense out of antisense for the study of drug receptors. J. Clin. Invest. 98:1996;1074-1075.
87. 2 by annexin V in differentiated permeabilized HL-60 cells. J. Biochem. 272:1997;10474-10482.
88. 2. Crit. Rev. Immunol. 17:1997;225-283.
89. 2 activity enriched in the nerve growth cone. J. Neurochem. 67:1996;2599-2608.
90. 2 inhibitors. J. Med. Chem. 34:1991;2260-2267.
91. Pavani M., Fones E., Oksenberg D., Garcia M., Hernandez C., Cordano G., Munoz S., Mancilla J., Guerrero A., Ferreira J. Inhibition of tumoral cell respiration and growth by nordihydroguaiaretic acid. Biochem. Pharmacol. 48:1994;1935-1942.
92. Pentland A.P., Morrison A.R., Jacobs S.C., Hruza L.L., Hebert J.S., Packer L. Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. J. Biol. Chem. 267:1992;15578-15584.
93. Pepinsky R.B., Tizard R., Mattaliano R.J., Sinclair L.K., Miller G.T., Browning J.L., Chow E.P., Burne C., Huang K.-S., Pratt D., Wachter L., Hession C., Frey A.Z., Wallner B.P. Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J. Biol. Chem. 263:1988;10799-10811.
94. Phillis, J. W. Cerebroprotective action of the phospholipase inhibitor quinacrine in the ischemia/reperfused gerbil hippocampus. Life Sci. 58:PL97-PL101; 1996.
95. 2 from rabbit kidney. J. Biol. Chem. 271:1996;15451-15457.
96. Ray P., Ray R., Broomfield C.A., Berman J.D. Inhibition of bioenergetics alters intracellular calcium, membrane composition, and fluidity in a neuronal cell line. Neurochem. Res. 19:1994;57-63.
97. Raynal P., Pollard H.B. Annexins The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins . Biochim. Biophys. Acta. 1197:1994;63-93.
98. Relton J.K., Strijbos P.J.L.M., O'Shaughnessy C.T., Carey F., Forder R.A., Tilders F.J.H., Rothwell N.J. Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain. J. Exp. Med. 174:1991;305-310.
99. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem. 269:1994;15619-15624.
100. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
101. 2) activity in gerbil brain Enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion . J. Neurosci. 11:1991;1829-1836.
102. 2 . Arch. Gen. Psychiatry. 54:1997;487-494.
103. 2 activity in human brain. J. Neurochem. 64:1995;2213-2221.
104. Rothman S.M., Yamada K.A., Lancaster N. Nordihydroguaiaretic acid attenuates NMDA neurotoxicity - Action beyond the receptor. Neuropharmacology. 32:1993;1279-1288.
105. 2 and cyclooxygenase-2 in the hippocampus after kainate lesions. Brain Res. 788:223-231.
106. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman D.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1997;1216-1222.
107. Schapira A.H.V. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol. 9:1996;260-264.
108. 1 ganglioside treatment . J. Neurosci. Res. 31:1992;112-119.
109. Shohami E., Beit-Yannai E., Horowitz M., Kohen R. Oxidative stress in closed-head injury Brain antioxidant capacity as an indicator of functional outcome . J. Cereb. Blood Flow Metab. 17:1997;1007-1019.
110. 2 is activated after experimental closed head injury in the rat. J. Neurochem. 53:1989;1541-1546.
111. 2-derived arachidonic acid and its metabolites. Brain Res. 721:1996;39-48.
112. 2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis. 3:1996;51-63.
113. 2) is expressed in human brain astrocytes. Brain Res. 637:1994;97-105.
114. 2+] in HIT insulinoma cells. J. Lipid Mediat. Cell Signal. 17:1997;65-70.
115. 2. Biochemistry. 32:1993;5935-5940.
116. 2 inhibitors on axon elongation. Int. J. Dev. Neurosci. 4:1986;363-367.
117. Suburo A.M., Cei de Job C. Early changes of surface morphology in monolayer cultures of neural retina cells. The effect of p-bromophenacyl bromide. Int. J. Dev. Neurosci. 5:1987;407-415.
118. Svennerholm L. Gangliosides - A new therapeutic agent against stroke and Alzheimer's disease. Life Sci. 55:1994;2125-2134.
119. Taylor, W. A. Effects of impact injury of rat spinal cord on activities of some enzymes of lipid hydrolysis. Doctoral dissertation, The Ohio State University, Columbus, OH; 1988.
120. Tazaki Y., Sakai H., Otomo E. Treatment of cerebral infarction with a choline precursor in a multi-center double blind placebo-controlled study. Stroke. 19:1988;211-216.
121. 2 function. Cancer Lett. 107:1996;59-64.
122. 2 from rat brain. Biochem. J. 306:1995;305-309.
123. 2 in Ehrlich ascites tumor cells. J. Membr. Biol. 160:1997;47-58.
124. 2 gene family in mammals. J. Biol. Chem. 272:1997;17247-17250.
125. Traber M.G., Packer L. Vitamin E Beyond antioxidant function . Am. J. Clin. Nutr. 62:1995;1501S-1509S.
126. 2 activity in rat heart myoblastic cells. Biochem. J. 319:1996;385-391.
127. 2. Biochemistry. 32:1993;12560-12565.
128. Vanags D.M., Larsson P., Feltenmark S., Jakobsson P.-J., Orrenius S., Claesson H.-E., Aguilar-Santelises M. Inhibitors of arachidonic acid metabolism reduce DNA and nuclear fragmentation induced by TNF plus cycloheximide in U937 cells. Cell Death Differ. 4:1997;479-486.
129. 2 in human melanoma tumor cells. J. Immunol. 156:1996;201-207.
130. Volterra A., Trotti D., Tromba C., Floridi S., Racagni G. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J. Neurosci. 14:1994;2924-2932.
131. 2 and CoA-independent transacylase. J. Lipid Mediat. Cell Signal. 10:1994;315-330.
132. 2. J. Biol. Chem. 271:1996;30879-30885.
133. 2. FEBS Lett. 377:1995;358-362.
134. 2. J. Biol. Chem. 272:1997;17145-17153.
135. Wurtman R.J., Sandage B.W. Jr, Warach S. Advances in understanding cholinergic brain neurons Implications in the use of citicholine (CDP-choline) to treat stroke . Becker R., Giacobini E. Alzheimer's disease From molecular biology to therapy . 1996;179-185 Birkhauser, Boston.
136. 2 levels in patients with advanced cancer. Clin. Chim. Acta. 228:1994;91-99.
137. Yanaka K., Spellman S.R., McCarthy J.B., Low W.C., Camarata P.J. Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. 2. Dose-response effect and the therapeutic window. J. Neurosurg. 85:1996;1108-1112.
138. 2 from bovine brain. Biochem. J. 299:1994;91-95.
139. 2 from bovine brain. Biochem. Biophys. Res. Commun. 199:1994;1158-1166.
140. 2 from bovine brain. Prostaglandins Leukot. Essent. Fatty Acids. 55:1996;111.
141. Yoshida H., Tsujishita Y., Hullin F., Yoshida K., Nakamura S., Kikkawa U., Asaoka Y. Isolation and properties of a novel phospholipase A from rat brain that hydrolyses fatty acids at sn-1 and sn-2 positions. Ann. Clin. Biochem. 35:1998;295-301.
142. 2 from cytosol to membranes in rat brain induced by calcium ions. Biochem. Biophys. Res. Commun. 170:1990;484-490.
143. 2. J. Med. Chem. 36:1993;95-100.